Business
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% r
About this update from Seres Therapeutics, Inc.
[{"type":"image","alt":"Seres Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Seres Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":205,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/c9212fd90ce8aaab0f99113fa1623d37"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/k2NwaR5ktGr5v1rR6gsPpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE0OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c9212fd90ce8aaab0f99113fa1623d37","width":205,"height":85}},"lazy":false},{"type":"text","content":"In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies","length":300,"tagName":"p"},{"type":"text","content":"SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support broader potential for Seres’ live biotherapeutics to address inflammatory and immune diseases","length":337,"tagName":"p"},{"type":"text","content":"Seres advancing SER-155 strategic partnership discussions in support of further development in allo-HSCT and potential expansion into other target populations","length":158,"tagName":"p"},{"type":"text","content":"Conference call at 8:30 a.m. ET today ","length":47,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported first quarter 2025 financial results and provided business updates.","length":243,"tagName":"p"},{"type":"text","content":"“Advancing SER-155 through the next stage of development remains our top corporate priority, and we are making significant progress toward initiating the next clinical study,” said Eric Shaff, President and Chief Executive Officer of Seres. “The clinical results generated to date underscore the potential of SER-155 to redefine the standard of care for allo-HSCT recipients and other vulnerable patients at risk of bloodstream infections— addressing a significant un...